MedTrace Logo

A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors

NCT05010525 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-03-17

No results posted yet for this study

Summary

This is A Phase Ib/II Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients with Advanced Solid Tumors

Conditions

Interventions

DRUG

ATG-016

48 patients enrolled, orally, each 3 week (21-day) a cycle

Sponsors & Collaborators

  • Shanghai Antengene Corporation Limited

    lead INDUSTRY

Principal Investigators

  • Yongsheng Wang, PhD · Guoxue lane, Chengdu, Sichuan

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-11-14
Completion
2022-11-14

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05010525 on ClinicalTrials.gov